Change in lipids and lipoproteins in relation to the ACE and AT1R genotypes for patients randomised to placebo or pravastatin treatment
| ACE DD genotype: | − | + | − | + | p Value | |
|---|---|---|---|---|---|---|
| AT1R CC genotype: | − | − | + | + | ||
| Placebo | ||||||
| Number of patients | 232 | 85 | 26 | 15 | ||
| Total cholesterol (mmol/l) | 0.18 (0.72) | 0.09 (0.82) | 0.06 (0.56) | 0.11 (1.01) | 0.73 | |
| HDL cholesterol (mmol/l) | 0.03 (0.15) | 0.03 (0.14) | 0.01 (0.13) | 0.05 (0.26) | 0.85 | |
| LDL cholesterol (mmol/l) | 0.04 (0.67) | −0.01 (0.65) | −0.13 (0.48) | −0.07 (0.79) | 0.56 | |
| Triglycerides (mmol/l) | 0.21 (0.81) | 0.12 (0.74) | 0.40 (0.84) | 0.53 (0.98) | 0.20 | |
| Pravastatin | ||||||
| Number of patients | 252 | 82 | 20 | 9 | ||
| Total cholesterol (mmol/l) | −1.31 (0.86) | −1.46 (0.77) | −1.17 (1.11) | −0.87 (0.82) | 0.14 | |
| HDL cholesterol (mmol/l) | 0.11 (0.17) | 0.09 (0.18) | 0.11 (0.16) | −0.01 (0.08) | 0.26 | |
| LDL cholesterol (mmol/l) | −1.36 (0.78) | −1.46 (0.64) | −1.28 (0.92) | −0.90 (0.94) | 0.23 | |
| Triglycerides (mmol/l) | −0.13 (0.73) | −0.22 (0.67) | −0.02 (0.84) | −0.06 (0.61) | 0.52 | |
Values are mean change (SD). Change is defined as follow up measurement minus baseline measurement.